Keywords: USA, FDA, Novartis, Afinitor, Forest Labs, Teflaro, Avenir, Nuedexta, Votubiam Pseudobulbar, Cell astrocytoma, Bacterial infections
US FDA approves Novartis Afinitor for SEGA, Forest’s Teflaro for CABP and Avanir’s Nuedexta for PBA
Article | 01 November 2010
The US Food and Drug Administration has approved Swiss drug major Novartis’ (NOVN: VX) Afinitor (everolimus) tablets for patients ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
